DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Quarter Results
BB Biotech AG reports preliminary results
11-Oct-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media Release, October 11, 2018
BB Biotech AG reports preliminary results
In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of September 30, 2018.
Based on preliminary unaudited consolidated results, BB Biotech AG reports for the nine months period ended September 30, 2018 a profit of CHF 172 million (CHF 843 million in the corresponding period of the previous year). In the third quarter a profit of CHF 242 million (profit of CHF 365 million in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.
Since beginning of the year, BB Biotech's share price increased 16.8% in CHF and 18.4% in EUR.
The interim report as of September 30, 2018 will be published on October 19, 2018.
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
11-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone:
+41 52 624 08 45
E-mail:
info@bbbiotech.com
Internet:
www.bbbiotech.ch
ISIN:
CH0038389992
WKN:
A0NFN3
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.